PDB Short entry for 4CLI HEADER TRANSFERASE 14-JAN-14 4CLI TITLE STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF- TITLE 2 06463922 ((10R)-7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15,16, TITLE 3 17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO(4,3-H)(2,5,11) TITLE 4 BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE). COMPND MOL_ID: 1; COMPND 2 MOLECULE: ALK TYROSINE KINASE RECEPTOR; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: TYROSINE KINASE DOMAIN, RESIDUES 1093-1411; COMPND 5 SYNONYM: ANAPLASTIC LYMPHOMA KINASE, CD246; COMPND 6 EC: 2.7.10.1; COMPND 7 ENGINEERED: YES; COMPND 8 OTHER_DETAILS: NONPHOSPHORYLATED SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 8 EXPRESSION_SYSTEM_CELL_LINE: SF9; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PFASTBAC KEYWDS TRANSFERASE, INHIBITOR EXPDTA X-RAY DIFFRACTION AUTHOR M.A.MCTIGUE,Y.L.DENG,W.LIU,A.BROOUN,A.E.STEWART REVDAT 4 20-DEC-23 4CLI 1 REMARK REVDAT 3 08-MAY-19 4CLI 1 REMARK REVDAT 2 25-JUN-14 4CLI 1 JRNL REMARK REVDAT 1 28-MAY-14 4CLI 0 JRNL AUTH T.W.JOHNSON,P.F.RICHARDSON,S.BAILEY,A.BROOUN,B.J.BURKE, JRNL AUTH 2 M.R.COLLINS,J.J.CUI,J.G.DEAL,Y.L.DENG,D.M.DINH,L.D.ENGSTROM, JRNL AUTH 3 M.HE,J.E.HOFFMAN,R.L.HOFFMAN,Q.HUANG,J.KATH,R.S.KANIA,H.LAM, JRNL AUTH 4 J.L.LAM,P.T.LE,L.LINGARDO,W.LIU,M.A.MCTIGUE,C.L.PALMER, JRNL AUTH 5 N.W.SACH,T.SMEAL,G.L.SMITH,A.E.STEWART,S.L.TIMOFEEVSKI, JRNL AUTH 6 H.ZHU,J.ZHU,H.Y.ZOU,M.P.EDWARDS JRNL TITL DISCOVERY OF JRNL TITL 2 (10R)-7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15,16, JRNL TITL 3 17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO[4,3-H][2,5, JRNL TITL 4 11]BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE JRNL TITL 5 (PF-06463922), A MACROCYCLIC INHIBITOR OF ALK/ROS1 WITH JRNL TITL 6 PRE-CLINICAL BRAIN EXPOSURE AND BROAD SPECTRUM POTENCY JRNL TITL 7 AGAINST ALK-RESISTANT MUTATIONS. JRNL REF J.MED.CHEM. V. 57 4720 2014 JRNL REFN ISSN 0022-2623 JRNL PMID 24819116 JRNL DOI 10.1021/JM500261Q REMARK 2 REMARK 2 RESOLUTION. 2.05 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2005 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.05 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 52.51 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 31364.930 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 94.8 REMARK 3 NUMBER OF REFLECTIONS : 35891 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.199 REMARK 3 R VALUE (WORKING SET) : 0.198 REMARK 3 FREE R VALUE : 0.245 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 3.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1103 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.007 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.2000 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.1990 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.245 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 3.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 1140 REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : 0.0070 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 37677 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.05 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.18 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 88.00 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 5398 REMARK 3 BIN R VALUE (WORKING SET) : 0.2620 REMARK 3 BIN FREE R VALUE : 0.3170 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 2.70 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 151 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.026 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2314 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 30 REMARK 3 SOLVENT ATOMS : 232 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 16.00 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 29.20 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -2.61000 REMARK 3 B22 (A**2) : -4.27000 REMARK 3 B33 (A**2) : 6.87000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.22 REMARK 3 ESD FROM SIGMAA (A) : 0.23 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.29 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.27 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 BOND ANGLES (DEGREES) : 0.800 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 19.50 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.660 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.490 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.410 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.360 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.440 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.38 REMARK 3 BSOL : 62.82 REMARK 3 REMARK 3 NCS MODEL : NONE REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : DNA-RNA_REP.PARAM REMARK 3 PARAMETER FILE 3 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 4 : ION.PARAM REMARK 3 PARAMETER FILE 5 : UNL.PARAM REMARK 3 PARAMETER FILE 6 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : DNA-RNA.TOP REMARK 3 TOPOLOGY FILE 3 : WATER.TOP REMARK 3 TOPOLOGY FILE 4 : ION.TOP REMARK 3 TOPOLOGY FILE 5 : UNL.TOP REMARK 3 TOPOLOGY FILE 6 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4CLI COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 14-JAN-14. REMARK 100 THE DEPOSITION ID IS D_1290059394. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 03-FEB-12 REMARK 200 TEMPERATURE (KELVIN) : 87 REMARK 200 PH : 5.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : DIAMOND REMARK 200 BEAMLINE : I03 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.976 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 23831 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.940 REMARK 200 RESOLUTION RANGE LOW (A) : 52.510 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 200 DATA REDUNDANCY : 6.500 REMARK 200 R MERGE (I) : 0.11000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 12.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.94 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.99 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.8 REMARK 200 DATA REDUNDANCY IN SHELL : 6.40 REMARK 200 R MERGE FOR SHELL (I) : 0.77000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.800 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNX REMARK 200 STARTING MODEL: PDB ENTRY 2XP2 REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 41.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.10 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: HANGING DROP VAPOR DIFFUSION AT 13 REMARK 280 DEGREES C. EQUAL VOLUMES OF PURIFIED PROTEIN SOLUTION REMARK 280 (APPROXIMATELY 13-15 MG/ML)CONTAINING 0.0011M INHIBITOR COMPOUND REMARK 280 WERE COMBINED WITH A SOLUTION CONTAINING: 0.15M AMMONIUM SULFATE, REMARK 280 9-10.5% MONOMETHYLETHER PEG5K AND 0.1M MES IN THE PH RANGE 5.3- REMARK 280 6.5, PH 5.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 286K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.88000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 52.51000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 28.64000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 52.51000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.88000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 28.64000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1085 REMARK 465 ALA A 1086 REMARK 465 HIS A 1087 REMARK 465 HIS A 1088 REMARK 465 HIS A 1089 REMARK 465 HIS A 1090 REMARK 465 HIS A 1091 REMARK 465 HIS A 1092 REMARK 465 SER A 1136 REMARK 465 GLY A 1137 REMARK 465 MET A 1138 REMARK 465 PRO A 1139 REMARK 465 ASN A 1140 REMARK 465 ASP A 1141 REMARK 465 PRO A 1142 REMARK 465 SER A 1143 REMARK 465 ALA A 1280 REMARK 465 SER A 1281 REMARK 465 TYR A 1282 REMARK 465 TYR A 1283 REMARK 465 ARG A 1284 REMARK 465 LYS A 1285 REMARK 465 GLY A 1402 REMARK 465 PRO A 1403 REMARK 465 LEU A 1404 REMARK 465 VAL A 1405 REMARK 465 GLU A 1406 REMARK 465 GLU A 1407 REMARK 465 GLU A 1408 REMARK 465 GLU A 1409 REMARK 465 LYS A 1410 REMARK 465 VAL A 1411 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 TYR A1401 CA C O CB CG CD1 CD2 REMARK 470 TYR A1401 CE1 CE2 CZ OH REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 HIS A1124 -71.94 -134.81 REMARK 500 ALA A1126 -177.15 -57.07 REMARK 500 PHE A1127 91.39 -64.28 REMARK 500 GLN A1217 69.62 -110.78 REMARK 500 ARG A1248 -9.07 81.47 REMARK 500 ASP A1249 55.02 -150.64 REMARK 500 SER A1332 1.97 83.72 REMARK 500 GLU A1400 88.84 -45.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2022 DISTANCE = 5.82 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 5P8 A 2401 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4CLJ RELATED DB: PDB REMARK 900 STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN REMARK 900 COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12 -FLUORO-2,10,16- REMARK 900 TRIMETHYL-15-OXO-10,15,16,17- TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO(4, REMARK 900 3-H)(2,5, 11)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE). REMARK 900 RELATED ID: 4CMO RELATED DB: PDB REMARK 900 STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH REMARK 900 THE INHIBITOR 2-((1R)-1-((3-AMINO-6-( 2-METHOXYPYRIDIN-3-YL)PYRAZIN- REMARK 900 2-YL)OXY)ETHYL)-4- FLUORO-N-METHYLBENZAMIDE REMARK 900 RELATED ID: 4CMT RELATED DB: PDB REMARK 900 STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH REMARK 900 THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-( 2H-1,2,3-TRIAZOL-2-YL)PHENYL) REMARK 900 ETHOXY)-5-(3-( METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE REMARK 900 RELATED ID: 4CMU RELATED DB: PDB REMARK 900 STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH REMARK 900 THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1 ,3,10,16-TETRAMETHYL-16,17- REMARK 900 DIHYDRO-1H-8,4-( METHENO)PYRAZOLO(4,3-H)(2,5,11) REMARK 900 BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE REMARK 999 REMARK 999 SEQUENCE REMARK 999 RESIDUES 1093-1411 OF HUMAN ANAPLASTIC LYMPHOMA KINASE REMARK 999 PLUS AN ENGINEERED N-TERMINAL HIS-TAG. DBREF 4CLI A 1093 1411 UNP Q9UM73 ALK_HUMAN 1093 1411 SEQADV 4CLI MET A 1085 UNP Q9UM73 EXPRESSION TAG SEQADV 4CLI ALA A 1086 UNP Q9UM73 EXPRESSION TAG SEQADV 4CLI HIS A 1087 UNP Q9UM73 EXPRESSION TAG SEQADV 4CLI HIS A 1088 UNP Q9UM73 EXPRESSION TAG SEQADV 4CLI HIS A 1089 UNP Q9UM73 EXPRESSION TAG SEQADV 4CLI HIS A 1090 UNP Q9UM73 EXPRESSION TAG SEQADV 4CLI HIS A 1091 UNP Q9UM73 EXPRESSION TAG SEQADV 4CLI HIS A 1092 UNP Q9UM73 EXPRESSION TAG SEQRES 1 A 327 MET ALA HIS HIS HIS HIS HIS HIS ASN PRO ASN TYR CYS SEQRES 2 A 327 PHE ALA GLY LYS THR SER SER ILE SER ASP LEU LYS GLU SEQRES 3 A 327 VAL PRO ARG LYS ASN ILE THR LEU ILE ARG GLY LEU GLY SEQRES 4 A 327 HIS GLY ALA PHE GLY GLU VAL TYR GLU GLY GLN VAL SER SEQRES 5 A 327 GLY MET PRO ASN ASP PRO SER PRO LEU GLN VAL ALA VAL SEQRES 6 A 327 LYS THR LEU PRO GLU VAL CYS SER GLU GLN ASP GLU LEU SEQRES 7 A 327 ASP PHE LEU MET GLU ALA LEU ILE ILE SER LYS PHE ASN SEQRES 8 A 327 HIS GLN ASN ILE VAL ARG CYS ILE GLY VAL SER LEU GLN SEQRES 9 A 327 SER LEU PRO ARG PHE ILE LEU LEU GLU LEU MET ALA GLY SEQRES 10 A 327 GLY ASP LEU LYS SER PHE LEU ARG GLU THR ARG PRO ARG SEQRES 11 A 327 PRO SER GLN PRO SER SER LEU ALA MET LEU ASP LEU LEU SEQRES 12 A 327 HIS VAL ALA ARG ASP ILE ALA CYS GLY CYS GLN TYR LEU SEQRES 13 A 327 GLU GLU ASN HIS PHE ILE HIS ARG ASP ILE ALA ALA ARG SEQRES 14 A 327 ASN CYS LEU LEU THR CYS PRO GLY PRO GLY ARG VAL ALA SEQRES 15 A 327 LYS ILE GLY ASP PHE GLY MET ALA ARG ASP ILE TYR ARG SEQRES 16 A 327 ALA SER TYR TYR ARG LYS GLY GLY CYS ALA MET LEU PRO SEQRES 17 A 327 VAL LYS TRP MET PRO PRO GLU ALA PHE MET GLU GLY ILE SEQRES 18 A 327 PHE THR SER LYS THR ASP THR TRP SER PHE GLY VAL LEU SEQRES 19 A 327 LEU TRP GLU ILE PHE SER LEU GLY TYR MET PRO TYR PRO SEQRES 20 A 327 SER LYS SER ASN GLN GLU VAL LEU GLU PHE VAL THR SER SEQRES 21 A 327 GLY GLY ARG MET ASP PRO PRO LYS ASN CYS PRO GLY PRO SEQRES 22 A 327 VAL TYR ARG ILE MET THR GLN CYS TRP GLN HIS GLN PRO SEQRES 23 A 327 GLU ASP ARG PRO ASN PHE ALA ILE ILE LEU GLU ARG ILE SEQRES 24 A 327 GLU TYR CYS THR GLN ASP PRO ASP VAL ILE ASN THR ALA SEQRES 25 A 327 LEU PRO ILE GLU TYR GLY PRO LEU VAL GLU GLU GLU GLU SEQRES 26 A 327 LYS VAL HET 5P8 A2401 30 HETNAM 5P8 (10R)-7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15, HETNAM 2 5P8 16,17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO[4,3-H][2,5, HETNAM 3 5P8 11]BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE FORMUL 2 5P8 C21 H19 F N6 O2 FORMUL 3 HOH *232(H2 O) HELIX 1 1 SER A 1104 LEU A 1108 5 5 HELIX 2 2 PRO A 1112 ILE A 1116 5 5 HELIX 3 3 SER A 1157 PHE A 1174 1 18 HELIX 4 4 LEU A 1204 THR A 1211 1 8 HELIX 5 5 ALA A 1222 ASN A 1243 1 22 HELIX 6 6 ALA A 1251 ARG A 1253 5 3 HELIX 7 7 PHE A 1271 ARG A 1279 1 9 HELIX 8 8 GLY A 1287 LEU A 1291 5 5 HELIX 9 9 PRO A 1292 MET A 1296 5 5 HELIX 10 10 PRO A 1297 GLY A 1304 1 8 HELIX 11 11 THR A 1307 SER A 1324 1 18 HELIX 12 12 SER A 1334 SER A 1344 1 11 HELIX 13 13 PRO A 1355 TRP A 1366 1 12 HELIX 14 14 GLN A 1369 ARG A 1373 5 5 HELIX 15 15 ASN A 1375 ASP A 1389 1 15 HELIX 16 16 ASP A 1389 ASN A 1394 1 6 SHEET 1 AA 2 TYR A1096 PHE A1098 0 SHEET 2 AA 2 LYS A1101 SER A1103 -1 O LYS A1101 N PHE A1098 SHEET 1 AB 5 THR A1117 GLY A1123 0 SHEET 2 AB 5 VAL A1130 GLN A1134 -1 O VAL A1130 N LEU A1122 SHEET 3 AB 5 GLN A1146 THR A1151 -1 O VAL A1147 N GLY A1133 SHEET 4 AB 5 PHE A1193 GLU A1197 -1 O ILE A1194 N LYS A1150 SHEET 5 AB 5 CYS A1182 SER A1186 -1 N ILE A1183 O LEU A1195 SHEET 1 AC 3 GLY A1202 ASP A1203 0 SHEET 2 AC 3 CYS A1255 LEU A1257 -1 N LEU A1257 O GLY A1202 SHEET 3 AC 3 ALA A1266 ILE A1268 -1 O LYS A1267 N LEU A1256 CISPEP 1 LEU A 1190 PRO A 1191 0 -4.58 SITE 1 AC1 14 LEU A1122 VAL A1130 ALA A1148 LEU A1196 SITE 2 AC1 14 GLU A1197 LEU A1198 MET A1199 ARG A1253 SITE 3 AC1 14 ASN A1254 LEU A1256 GLY A1269 ASP A1270 SITE 4 AC1 14 HOH A2060 HOH A2093 CRYST1 51.760 57.280 105.020 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019320 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017458 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009522 0.00000